The asthma medication omalizumab (Xolair) has demonstrated effectiveness in treating seasonal allergies during initial clinical trials. Administered as a monoclonal antibody, it works by targeting immunoglobulin E, preventing allergic responses at their source. In contrast to traditional antihistamines, which only alleviate symptoms like runny noses but may not be effective for everyone, omalizumab requires only one injection administered ahead of allergy season, offering sustained relief by addressing multiple allergens simultaneously. Experts suggest this class of treatments may significantly improve allergy management.
Omalizumab, sold as Xolair, is a monoclonal antibody that effectively treats seasonal allergies by targeting the underlying pathways of allergic reactions.
Unlike antihistamines like Claritin or Zyrtec, which target symptoms, monoclonal antibodies like omalizumab address the underlying issue, providing longer-lasting relief.
Sayantani Sindher emphasizes the benefit of antibody-based therapeutics, stating they can impact all of a patient's allergens simultaneously, not just individual symptoms.
Omalizumab requires just one injection two weeks before allergy season, which is more convenient compared to daily doses of traditional antihistamines.
Collection
[
|
...
]